Streetbeat News

Analyst Ratings

CNTX

HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating for Context Therapeutics (NASDAQ:CNTX) and maintained a price target of $6.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 5:21 pm

BHVN

Baird analyst Brian Skorney maintains an Outperform rating on Biohaven (NYSE:BHVN) and raises the price target from $58 to $60.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 5:20 pm

CIEN

GM

INTC

QCOM

TSLA

VKTX

US stocks opened the week flat as investors await clarity on economic and political fronts. Gold hit record highs, while Tesla surged 4% amid a proposed export ban on Chinese vehicles. Intel rose on Qualcomm takeover rumors, and Ciena received a double upgrade from Citigroup.

Portfolio Pulse from Piero Cingari

September 23, 2024 | 5:20 pm

BLCO

HC Wainwright & Co. analyst Yi Chen maintains a Buy rating on Bausch & Lomb (NYSE:BLCO) and raises the price target from $19 to $22.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 5:17 pm

CVS

CVS Health is experiencing a surge in options activity, with a significant portion of investors adopting a bearish stance. The options activity includes 32 notable trades, with 56% of investors leaning bearish. The stock is currently trading at $57.8, with analysts setting an average price target of $64.0. Recent analyst ratings have been revised downward.

Portfolio Pulse from Benzinga Insights

September 23, 2024 | 5:16 pm

TNDM

Morgan Stanley analyst Patrick Wood maintains an Equal-Weight rating on Tandem Diabetes Care with a $45 price target.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 5:12 pm

MC

Morgan Stanley analyst Ryan Kenny maintains an Underweight rating on Moelis (NYSE:MC) but raises the price target from $61 to $67.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 5:11 pm

AMZN

GOOGL

MSFT

NVDA

DA Davidson analyst Gil Luria downgraded Microsoft to Neutral, citing increased competition from Amazon and Google in AI and cloud services. Microsoft's lead in AI has diminished, impacting its premium valuation. The company faces challenges in maintaining its growth and margins.

Portfolio Pulse from Anusuya Lahiri

September 23, 2024 | 5:10 pm

LAZ

Morgan Stanley analyst Ryan Kenny has maintained an Overweight rating on Lazard (NYSE:LAZ) and increased the price target from $56 to $60.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 5:09 pm

HLI

Morgan Stanley has maintained an Equal-Weight rating on Houlihan Lokey and raised its price target from $146 to $163.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 5:07 pm